Press Release — New York, NY — December 15, 2016 — Sichenzia Ross Ference Kesner LLP (“SRFK”) has represented Alzamend Neuro, Inc., a company formed with the intention of preventing, treating and curing Alzheimer’s, in its effort to qualify its Offering Statement on Form 1-A pursuant to Regulation A+. The Offering Statement was qualified by the Securities & Exchange Commission on December 8, 2016. The Sichenzia Ross Ference Kesner LLP team was led by Partners Marc Ross and Henry Nisser. Mr. Ross commented that “We found this to be a very interesting project and believe that issuers such as Alzamend Neuro stand to benefit tremendously from the adoption of Reg A+.” Mr. Nisser stated that “We are very pleased with Alzamend’s success in having its Offering Statement qualified by the SEC and look forward to working with its principals as they move forward with the offering and hopefully subsequent development of a treatment for Alzheimer’s.”
[starbox id =1]
